Ovoca Gold PLC (OVXA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ovoca Gold PLC (OVXA) has a cash flow conversion efficiency ratio of -0.067x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-340.00K ≈ $-397.50K USD) by net assets (€5.06 Million ≈ $5.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View OVXA stock price and chart for real-time trading data and today's change.
Ovoca Gold PLC - Cash Flow Conversion Efficiency Trend (1991–2023)
This chart illustrates how Ovoca Gold PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market cap of Ovoca Gold PLC for the company's overall valuation and market capitalisation.
Ovoca Gold PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ovoca Gold PLC ranked by their cash flow conversion efficiency. Also see OVXA total asset value for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Tin PLC
LSE:1SN
|
-0.028x |
|
Hansard Global Plc
LSE:HSD
|
-0.013x |
|
Accelerate Diagnostics Inc
NASDAQ:AXDX
|
0.090x |
|
Regent Pacific Properties Inc
V:RPP
|
0.061x |
|
Topps Tiles PLC
LSE:TPT
|
2.160x |
|
Magnum Goldcorp Inc
V:MGI
|
0.167x |
|
Carr's Group plc
LSE:CARR
|
0.075x |
|
PDG Realty S.A. Empreendimentos e Participações
SA:PDGR3
|
0.000x |
Annual Cash Flow Conversion Efficiency for Ovoca Gold PLC (1991–2023)
The table below shows the annual cash flow conversion efficiency of Ovoca Gold PLC from 1991 to 2023. Review OVXA financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | €2.50 Million ≈ $2.92 Million |
€1.11 Million ≈ $1.30 Million |
0.446x | +165.91% |
| 2022-12-31 | €7.63 Million ≈ $8.93 Million |
€-5.16 Million ≈ $-6.04 Million |
-0.676x | -107.58% |
| 2021-12-31 | €13.43 Million ≈ $15.70 Million |
€-4.38 Million ≈ $-5.12 Million |
-0.326x | -186.35% |
| 2020-12-31 | €18.55 Million ≈ $21.69 Million |
€-2.11 Million ≈ $-2.47 Million |
-0.114x | -24.99% |
| 2019-12-31 | €23.84 Million ≈ $27.87 Million |
€-2.17 Million ≈ $-2.54 Million |
-0.091x | +33.83% |
| 2018-12-31 | €20.63 Million ≈ $24.11 Million |
€-2.84 Million ≈ $-3.32 Million |
-0.138x | -150.20% |
| 2017-12-31 | €22.40 Million ≈ $26.19 Million |
€-1.23 Million ≈ $-1.44 Million |
-0.055x | -227.60% |
| 2016-12-31 | €23.47 Million ≈ $27.44 Million |
€-394.00K ≈ $-460.63K |
-0.017x | -138.97% |
| 2015-12-31 | €21.45 Million ≈ $25.08 Million |
€924.00K ≈ $1.08 Million |
0.043x | +395.85% |
| 2014-12-31 | €22.46 Million ≈ $26.26 Million |
€-327.00K ≈ $-382.30K |
-0.015x | +86.58% |
| 2013-12-31 | €25.97 Million ≈ $30.37 Million |
€-2.82 Million ≈ $-3.29 Million |
-0.108x | -333.35% |
| 2012-12-31 | €48.62 Million ≈ $56.85 Million |
€2.26 Million ≈ $2.64 Million |
0.046x | -29.58% |
| 2011-12-31 | €50.15 Million ≈ $58.63 Million |
€3.31 Million ≈ $3.87 Million |
0.066x | +52.93% |
| 2010-12-31 | €56.75 Million ≈ $66.34 Million |
€2.45 Million ≈ $2.86 Million |
0.043x | -41.23% |
| 2009-12-31 | €46.42 Million ≈ $54.27 Million |
€3.41 Million ≈ $3.99 Million |
0.073x | +1163.67% |
| 2008-12-31 | €38.20 Million ≈ $44.66 Million |
€222.00K ≈ $259.54K |
0.006x | +117.38% |
| 2007-12-31 | €46.05 Million ≈ $53.84 Million |
€-1.54 Million ≈ $-1.80 Million |
-0.033x | -81.49% |
| 2006-12-31 | €30.83 Million ≈ $36.04 Million |
€-568.00K ≈ $-664.05K |
-0.018x | +57.83% |
| 2005-12-31 | €10.60 Million ≈ $12.39 Million |
€-463.00K ≈ $-541.30K |
-0.044x | +47.88% |
| 2004-12-31 | €4.41 Million ≈ $5.16 Million |
€-370.00K ≈ $-432.57K |
-0.084x | +13.55% |
| 2003-12-31 | €4.48 Million ≈ $5.23 Million |
€-434.00K ≈ $-507.39K |
-0.097x | -3503.35% |
| 2002-12-31 | €3.16 Million ≈ $3.69 Million |
€9.00K ≈ $10.52K |
0.003x | +105.19% |
| 2001-12-31 | €3.39 Million ≈ $3.96 Million |
€-186.00K ≈ $-217.45K |
-0.055x | -14.89% |
| 2000-12-31 | €3.14 Million ≈ $3.67 Million |
€-150.00K ≈ $-175.37K |
-0.048x | +18.22% |
| 1999-12-31 | €3.29 Million ≈ $3.84 Million |
€-192.00K ≈ $-224.47K |
-0.058x | +45.56% |
| 1998-12-31 | €3.29 Million ≈ $3.85 Million |
€-353.00K ≈ $-412.69K |
-0.107x | -325.41% |
| 1997-12-31 | €2.18 Million ≈ $2.55 Million |
€-55.00K ≈ $-64.30K |
-0.025x | +22.55% |
| 1996-12-31 | €1.93 Million ≈ $2.26 Million |
€-63.00K ≈ $-73.65K |
-0.033x | -2823.60% |
| 1994-12-31 | €1.79 Million ≈ $2.10 Million |
€-2.00K ≈ $-2.34K |
-0.001x | +96.94% |
| 1993-12-31 | €1.87 Million ≈ $2.18 Million |
€-68.00K ≈ $-79.50K |
-0.036x | -471.51% |
| 1992-12-31 | €1.12 Million ≈ $1.31 Million |
€11.00K ≈ $12.86K |
0.010x | +122.88% |
| 1991-12-31 | €1.12 Million ≈ $1.31 Million |
€-48.00K ≈ $-56.12K |
-0.043x | -- |
About Ovoca Gold PLC
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for women health. It's lead product is BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporate… Read more